Trials contractor to take equity in Peplin
Wednesday, 19 January, 2005
French-based clinical trial contractor Cvitkovic and Associates Consultants (CAC) will take equity in Brisbane cancer-drug developer Peplin Biotech (ASX:PEP) and establish a 'dedicated operation' in Australia.
Peplin's CEO, Michael Aldridge, said CAC has been working with Peplin for the past year on the early-stage cancer and leukaemia trials of its lead anti-cancer compound, PEP005.
In return for its contract clinical development services, CAC will take part-payment in Peplin shares, with quantities based on Peplin's price when quarterly payments fall due.
"The principals of CAC have a keen interest in our skin cancer, bladder cancer and leukaemia programs, and we have structured a long-term collaboration which will see an integration of activities and alignment of interests for both organisations," Aldridge said.
He described CAC as having world-class capabilities and cancer-focused expertise in designing, implementing, monitoring and reporting clinical trials.
The French company also had a strong track record in developing cancer drugs, and a 'solid presence' in the major pharmaceutical markets.
CAC's first project under the new agreement will be the Phase II clinical trial of PEP005 as a topical treatment for actinic keratoses - pre-cancerous 'sunspots'.
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
